Henry Ford Health

Henry Ford Health Scholarly Commons
Urology Articles

Urology

5-8-2021

Phase I trial of intravesical Bacillus Calmette-Guérin combined
with intravenous pembrolizumab in recurrent or persistent highgrade non-muscle-invasive bladder cancer after previous Bacillus
Calmette-Guérin treatment
Shaheen Alanee
Sherjeel Sana
Ahmed El-Zawahry
James O. Peabody
Henry Ford Health, JPEABOD1@hfhs.org

Tiffany Pearce
Henry Ford Health, tpearce1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/urology_articles

Recommended Citation
Alanee S, Sana S, El-Zawahry A, Peabody J, Pearce T, Adams N, Deebajah M, Crabtree J, Delfino K, McVary
K, Robinson K, and Rao K. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous
pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous
Bacillus Calmette-Guérin treatment. World J Urol 2021.

This Article is brought to you for free and open access by the Urology at Henry Ford Health Scholarly Commons. It
has been accepted for inclusion in Urology Articles by an authorized administrator of Henry Ford Health Scholarly
Commons.

Authors
Shaheen Alanee, Sherjeel Sana, Ahmed El-Zawahry, James O. Peabody, Tiffany Pearce, Nicole Adams,
Mustafa Deebajah, Jane Crabtree, Kristin Delfino, Kevin McVary, Kathy Robinson, and Krishna Rao

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
urology_articles/409

World Journal of Urology
https://doi.org/10.1007/s00345-021-03716-3

ORIGINAL ARTICLE

Phase I trial of intravesical Bacillus Calmette–Guérin combined
with intravenous pembrolizumab in recurrent or persistent
high‑grade non‑muscle‑invasive bladder cancer after previous Bacillus
Calmette–Guérin treatment
Shaheen Alanee1 · Sherjeel Sana2 · Ahmed El‑Zawahry3 · James Peabody4 · Tiffany Pearce4 · Nicole Adams4 ·
Mustafa Deebajah4 · Jane Crabtree6 · Kristin Delfino6 · Kevin McVary5 · Kathy Robinson6 · Krishna Rao6
Received: 9 March 2021 / Accepted: 27 April 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Objectives We conducted the first phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette–Guérin (BCG) in combination with systemic pembrolizumab in patients with high-grade non-muscle-invasive bladder cancer
(HGNMIBC) who had persistent or recurrent disease after prior intravesical therapy with BCG. The primary endpoint was
the safety of this combination. The secondary endpoint was clinical activity at three months following BCG treatment.
Methods Eighteen patients were consented for the study, five of which were screen failures. Six doses of pembrolizumab
were administered every 3 weeks over 16 weeks concurrently with six weekly doses of BCG beginning at week 7. Patient
safety was evaluated from the time of consent through 30 days following pembrolizumab treatment. Clinical activity was
determined using cystoscopy and biopsy of suspicious lesions.
Results Treatment-related adverse events included one grade 4 adverse event (AEs) (adrenal insufficiency). There were
nine grade 3 AEs (chest discomfort, pulmonary embolism, arthritis, wrist edema, injection site reaction, bilateral wrist pain,
cardiomyopathy, hypokalemia, urinary tract infection). There were 49 grade 1 and 30 grade 2 AEs (88% of AEs). Eleven
patients finished the treatment, and two patients died during the study. Of 13 patients treated, nine patients (69%) had no
evidence of disease at 3 months following BCG treatment.
Conclusions We report for the first time that combining BCG and pembrolizumab in treating HGNMIBC is safe allowing
complete treatment of most patients. A phase III trial has opened to test the efficacy of this combination in HGNMIBC
(KEYNOTE-676).
Keywords Bladder cancer · Non-muscle invasive · Pembrolizumab · Bacillus Calmette–Guérin · Cystectomy
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The standard of care for patients who have high-grade nonmuscle-invasive BCa (HGNMIBC) at presentation includes
conservative management through endoscopic resection
and intravesical instillation with BCG. More than half of
the patients treated with BCG develop recurrence and progression within the first year and many develop BCG-unresponsive disease in spite of a high (80%) initial complete
response to induction BCG [1–4]. Given that the only other
highly successful standard treatment for recurrent or persistent HGNMIBC is a radical cystectomy, a surgical modality
associated with a high degree of morbidity, identification of
alternative therapy is clearly warranted.
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Pembrolizumab is a potent humanized immunoglobulin
G4 (IgG4) mAb with high specificity of binding to PD-1
receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2). Previous studies have
identified that PD-L1 expression is exceptionally abundant
in BCG-induced bladder granulomata in patients failing
BCG treatment [5]. We hypothesized that a combination of
pembrolizumab and BCG following endoscopic surgery of
high-risk NMIBC is a safe combination and may be useful
in improving outcomes of NMIBC after endoscopic treatment in patients unfit or unwilling to be treated with radical
cystectomy.

Materials and methods
Patient population
This study enrolled patients with histologically confirmed
HGNMIBC who had recurrent/persistent disease after adequate BCG therapy or two induction courses of intravesical
therapy defined as two courses of BCG, BCG + mitomycin,
BCG + Gemcitabine, or BCG + BCG/interferon combination
in a 12-month time period. Patients with T1 disease were
required to have a restaging TURBT and patients resected
outside the study center were required to provide archival
tissue sample for central pathologic examination. Other key
inclusion criteria included Eastern Cooperative Oncology
Group performance status ≤ 2, and adequate organ function.
Patients with metastatic disease, history of autoimmune disease or immunodeficiency, prior PD-1 pathway therapy, or
CTLA-4 inhibitors and those currently receiving systemic
steroid therapy, were excluded. The study was approved by
the institutional review board at Southern Illinois University
and Henry Ford Health System (protocol SCRIHS 14-08B).
All patients provided written informed consent.

Study design
This was an investigator-initiated dose-escalation (3 + 3
design) Phase I safety study (NCT02324582) of pembrolizumab used in combination with bladder inserted BCG for
treatment of HGNMIBC (Fig. 1). Eligible patients initially
received a fixed dose of 100 mg pembrolizumab, given on
Day 1 (+ /‒3 days) of a 21-day cycle for 6 cycles for the first
3 subjects. After the first three subjects were treated at the
100 mg dose, the data safety review team made the determination that dose escalation to 200 mg was possible. All
remaining subjects were treated at 200 mg pembrolizumab
every 3 weeks for 6 cycles. BCG treatment (50 mg TICE
suspended in 50 ml of saline) was administered on day 1 of
cycle 3 (Week 7) of pembrolizumab-BCG treatment. BCG
treatment was repeated every 7 days at weeks 8, 9, 10, 11,
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and 12 of the study regimens. No dose modification was
attempted in this trial.

Primary and secondary endpoints
The primary objective was to determine the safety of administering pembrolizumab (100 mg and 200 mg dose) every
three weeks in conjunction with intravesical BCG treatment.
The secondary objective was to determine the no evidence
of disease (NED) rate using cystoscopy and cytology at
3 months following BCG treatment.

Statistical analysis
The number of patients who experienced each AE event was
tabulated. For each patient experiencing an AE, their AE
was dichotomously coded based on relation (i.e., “Definitely/
Possibly” vs “Unlikely/Unrelated”) to the ascribed causes of
pembrolizumab, BCG, and Bladder Cancer. Fisher’s exact
test was then used to determine if there was a significant
association between ascribed cause and relation [4]. P-values < 0.05 were considered statically significant.

Results
Baseline characteristics: Between June 30th, 2015, and September 11th, 2019, eighteen patients consented to the study,
and 13 patients received at least one dose of study treatment.
Patient characteristics, disease characteristics, and response
at 3 months following BCG treatment are summarized in
Table 1. Eighty-five percent (11/13) of subjects were male,
and 7% (1/13) were African American while the remainder
were Caucasian. Six patients had adequate intravesical BCG
as a condition for trial entry, while 38% (5/13) had prior
intravesical therapy with BCG followed by Mitomycin C and
15% (2/13) had intravesical therapy with BCG followed by
Gemcitabine. Only one patient had concurrent upper urinary
tract transitional cell carcinoma. The first patient consented
on June 30th 2015, and the final patient consented on September 11th 2019.
Safety and Tolerability: We summarized all treatmentrelated AEs in Table 2. Four patients (31%) developed
ten treatment-related grade 3/4 AEs. However, grade 3/4
AEs represented the minority of overall events with a rate
of 11%. Grade 3 treatment-related AEs included (chest
discomfort, arthritis, wrist edema, injection site reaction,
bilateral wrist pain, cardiomyopathy, hypokalemia, urinary
tract infection and pulmonary edema). The three grade
4 AEs were adrenal insufficiency, pulmonary embolism,
and hematuria. All but two of the grade 3/4 AEs resolved
with treatment (Adrenal insufficiency and arthritis are still
undergoing treatment). There were also 56 grade 1 and 2
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Fig. 1  Study design for phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent high-grade
non-muscle-invasive bladder cancer after previous Bacillus Calmette–Guérin treatment

treatment-related AEs (85% of AEs). Eleven patients finished the trial treatment (discontinuation rate of 15.4%).
Two patients died during the study period of causes unrelated to the trial treatment. The first patient had been diagnosed with low-grade upper urinary tract urothelial carcinoma and lower urinary tract urothelial carcinoma. The

patient’s upper urinary tract disease progressed while on
treatment, developed metastasis, and he died because of
that disease. He did not develop recurrence inside the bladder. The second patient presented with hematuria while
on trial treatment. He was then found to have muscleinvasive BCa and underwent radical cystoprostatectomy.
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Table 1  Patient characteristics, disease characteristics, and response
to treatment at 3 months post BCG Treatment for patients treated
with combination intravesical BCG and intravenous pembrolizumab

for high-grade non-muscle-invasive bladder cancer unresponsive to
previous BCG treatment

TURBT
Initial
immediately
Bladder
Cancer pathology prior to study
enrollment

Treatment
Prior to Study
Enrollment

Status at 3 Months
Post BCG
(19 weeks)

Caucasian 0

HGpTI

HGpTa

No recurrence

74

Caucasian 1

HGpTI

HGpTa

Male

55

Caucasian 0

HGpTI

HGpTa

Two courses of
BCG
Two courses of
BCG
BCG and Mitomycin

Subject 4

Male

61

Caucasian 0

HGpTa

CIS (subject also
had left renal
pelvis low-grade
papillary urothelial carcinoma)

Two courses of
BCG

Subject 6

Male

62

Caucasian 0

CIS

CIS

Subject 7

Male

73

Caucasian 0

HGpTa

HGpTa

Subject 8

Male

38

Caucasian 0

HGpTI

CIS

Subject 9

Male

80

Caucasian 0

HGpTI

CIS

Subject 10

Male

72

Black

2

HGpTI

CIS

Two courses of
BCG
BCG and Gemcitabine
BCG and Mitomycin
BCG and Mitomycin
BCG,
Gemcitabine and
Mitomycin

Subject 11

Male

61

Caucasian 1

HGpTa

HGpTI

Subject 13
Subject 14
Subject 15

Female 80
Female 89
Male
81

Caucasian 1
Caucasian 2
Caucasian 0

HGpTI
HGpTI
HGpTI

CIS
HGpTa
HgpTa

Patient (sequenced
by date of the
consent)

Gender Age Race

Subject 1

Male

75

Subject 2

Male

Subject 3

Performance
Status

Two courses of
BCG
*Adequate BCG
*Adequate BCG
BCG and Mitomycin

No recurrence
Recurrence with
high-grade noninvasive papillary urothelial
carcinoma. Focal
urothelial carcinoma in situ
Bladder Biopsies—
no recurrence;
progressive
low-grade papillary urothelial
carcinoma in left
renal pelvis and
lymph nodes
No recurrence
No recurrence
No recurrence
No recurrence
Invasive disease;
death subsequent
due to MACE
following cystectomy
recurrence with
HGpTa
No recurrence
No recurrence
No recurrence

Adequate BCG equates to 6 cycles of BCG followed by at least one course of BCG maintenance
*

Adequate BCG = at least 5 doses of induction + 2 maintenance doses of BCG

His postoperative course was uneventful, apart from nonspecific cardiac arrhythmia. He received a full workup
by cardiology, including cardiac catheterization, with no
significant findings. He was then discharged home. On
day two, after discharge, the patient lost consciousness
and was transferred to a nearby hospital, where he was
declared dead on arrival. A sudden cardiac event (grade
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5 event), unlikely related to the study treatment, was suspected to be the cause of this patient’s death.
Ascribed causes of the toxicities: We next examined
the relationship between AEs and the cause of the toxicity.
Due to the infrequent nature of most events, only a limited
set of toxicities could be examined and analyzed statistically. These events included cystitis, edema, fatigue, fever,
hematuria, hypothyroidism, insomnia, pain, and rash. For
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Table 2  Treatment-related adverse events in phase I trial of combination BCG and Pembrolizumab in the treatment of patients with highgrade non-muscle-invasive bladder cancer
Adverse event

Grade I
n = 49

Grade II
n = 30

Grade III
n=9

Endocrine
Respiratory
Gastrointestinal
Neurologic
Musculoskeletal
Cardiovascular and
edema
Genitourinary
Hepatobiliary
Electrolytes/metabolic
Skin and hair
Psychologic
Fever/chills
Fatigue

2
2
10
5
3

4
1
2
2
7
1

3
3

12
1
1
2
5
2
4

2

1

1
2
1
3
4

1
1

Grade IV
n=1
1

the purpose of this analysis, pain from any site in the
body was grouped into the general category of pain for
further analysis. Any of the aforementioned toxicities were
then examined for ascribed cause, either pembrolizumab,
BCG, or bladder cancer. For further analysis, a toxicity
was considered related to a noted cause if the cause was
coded as definitely related, probably related, or possibly
related (CTCAE V 4.0). Events were then pooled and analyzed. Of the toxicities, cystitis and hematuria were most
likely to be associated with BCG (p = 0.0562 and 0.0048,
respectively), while fatigue and pain were more likely
to be related to pembrolizumab (p = 0.0031 and 0.0048,
respectively).
As dose escalation was a fundamental part of this study,
toxicities were also examined for any relationship to the
dose escalation of pembrolizumab from 100 to 200 mg. As
with ascribed causes of toxicity, only a limited number of
toxicities could be analyzed due to low numbers of events.
None of the treatment toxicities displayed any significant
difference in frequency between the 100 mg and 200 mg
groups. The CTCAE grades of these toxicities were then
pooled into grades 1–4, and the severity of these toxicities
was then examined stratified by the two different dose levels.
Toxicities were more frequent in the 200 mg group with a
p-value < 0.005. Although toxicities were more frequent in
the 200 mg group, due to the minimal numbers, no further
analysis could be done beyond separating by dosage and
reporting of the overall frequencies.
Antitumor activity: Of the 13 patients treated, 9 had no
recurrence of HGNMIBC at three months following initiation of BCG treatment as measured by cystoscopy and cytology, representing a NED rate of 69%.

Discussion
The optimal alternative to the management of these
patients who are unfit or unwilling to undergo radical cystectomy remains unknown. This is the first trial to report
on the safety of combining of BCG and pembrolizumab in
treating HGNMIBC. If the combination of pembrolizumab
and BCG is found to be effective, it would provide patients
with an alternative to radical cystectomy and potentially
change the standard of care.
Kulkarni et al. reported on the results KEYNOTE-057;
a phase II study of pembrolizumab alone in patients with
NMIBC unresponsive to BCG. Patients then received
pembrolizumab 200 mg Q3W for 24 months. The authors
enrolled 103 patients (median age 73 years; CIS alone
71.8%; the median number of prior BCG instillations 12).
The authors reported a 3-month response (CR) rate of
38.8% (95% CI 29.4–48.9). KEYNOTE-057 also showed
that among patients who achieved CR at 3 months, 80.2%
of patients had a CR duration of at least 6 months. Grade
3/4 treatment-related AEs occurred in only 13 (12.6%)
patients. The results of KEYNOTE-057 led to an FDA
approval for pembrolizumab in patients with BCG-unresponsive high-grade transitional cell carcinoma with
CIS [6]. Based on our results, a phase III trial (KEYNOTE-676—NCT03711032) has been designed and is
currently open to test the efficacy of this combination in
patients with persistent or recurrent HR NMIBC after
BCG induction therapy. In this study, we allowed patients
with upper urinary tract urothelial carcinoma to receive
the trial treatment to enhance accrual and provide patients
unfit or unwilling to undergo radical surgery with another
treatment option. KEYNOTE-676 will exclude patients
with concurrent upper urinary urothelial carcinoma.
Parallel to the development of new combinations of
immunotherapy for the treatment of NMIBC, there are
other intravesical treatments being examined for BCGunresponsive disease. DeCastro et al. published the results
of a phase I trial of intravesical cabazitaxel, gemcitabine,
and cisplatin (CGC) for the management of treatmentunresponsive NMIBC [7]. This was a dose-escalation
drug trial enrolling patient with BCG refractory or recurrent high-risk NMIBC who refused or were ineligible for
radical cystectomy. All patients underwent a 6-week regimen of intravesical chemotherapy. The authors enrolled
18 patients and reported no dose-limiting toxicities and a
high initial complete response rate of 94%, and fourteen
patients (78%) remaining disease free at last follow-up. In
another study, Boorjian et al. reported on the results of a
phase III trial of Nadofaragene firadenovec (also known
as rAd-IFNa/Syn3), a replication-deficient recombinant
adenovirus that delivers human interferon alfa-2b cDNA
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into the bladder epithelium, for BCG-unresponsive nonmuscle-invasive bladder cancer. In this study, 157 patients
were enrolled and received at least one dose of the study
drug. On trial completion, 151 patients were included in
the per-protocol efficacy analyses and 55 (53·4%) of 103
patients with carcinoma in situ (with or without a highgrade Ta or T1 tumor) had a complete response within
3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drugrelated adverse event (two [1%] of 157 patients, both grade
3), and there were no treatment-related deaths. The authors
then concluded that their treatment was efficacious and
represents a novel treatment option for BCG-unresponsive
NMIBC [8].
We contend that the dual immunotherapy combination
of BCG and pembrolizumab has AEs rate within the range
expected for combined immunotherapy treatments in the
field of oncology. Nikanjam et al. reviewed the toxicity patterns of 3526 patients receiving a variety of immunotherapy
combinations with greater than one drug [9]. Their analysis
pooled 84 studies with 59 drug combinations. The authors
noted that although safety was acceptable for all doublet
combinations, “Only 9% of doublet immunotherapy combinations could be given at full dose, and the median safe
starting dose was at 50% of each single agent dose.” Likewise, biologic agents combined with immunotherapy could
be given at full dose in only 40% of studies. Our study demonstrated no requirement for dose reduction of either agent
with full doses of each agent being given. The combination
of ipilimumab and nivolumab, in the case of melanoma, has
led to high rates of toxicity, with a 53% grade 3–4 AEs. Discontinuation rates range from 36 to 47% [10, 11]. Shoushtari
et al. reported a 91% incidence of clinically significant AEs,
which led to ER visits, hospitalizations, and systemic immunosuppression [12]. Based on this contextual review of the
literature, it would appear that the combination of BCG and
pembrolizumab has a favorable toxicity profile, with a 11%
grade 3 or 4 toxicity rate and a 15.3% discontinuation rate.
Additionally, the dosage of 200 mg led to a higher frequency
of toxicities as compared to 100 mg. However, due to a small
number of events, no further analysis of severity could be
done.
It is imperative to remember that focus of this phase I
clinical trial has been to demonstrate that our combination of therapies is safe. The proof of treatment efficacy
will be established in a phase III trial (KEYNOTE-676).
In addition, like any other phase I trial, ethical issues need
to be considered as far as risks to subjects versus potential
benefits especially when some of the side effects could be
long lasting such as in the case of adrenal insufficiency. We
would also like to mention the extended time needed for the
trial accrual was related to our strict safety monitoring. Our
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safety committee reviewed the results after dose escalation
from 100 to 200 mg and then for major AE. Our independent
safety reviewers reviewed each AE, discussed their recommendations with the sponsor, and then allowed us to resume
the trial accrual after making sure the safety of the patients
was not compromised.

Conclusions
This study reports for the first time on the safety outcomes of
combining BCG and pembrolizumab in treating HGMIBC.
A phase III trial has opened to further study the efficacy and
safety of this combination (KEYNOTE-676).
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